The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways

MicroRNAs have been broadly implicated in cancer, but their exact function and mechanism in carcinogenesis remain poorly understood. Aberrant miR-486-5p expression is frequently found in human cancers. Here we showed a significant overexpression of miR-486-5p in prostate cancer compared with that in normal tissue and cells, and we proposed that altered expression of miR-486-5p in the prostate contributed to prostate cancer. Firstly, miR-486-5p inhibition expression reduced prostate cancercell proliferation, migration, and colonization in vitro and prostate tumor development in vivo. Moreover, we integrated RNA sequencing and target genes prediction, and systemically identified miR-486-5p candidate target genes. We conducted an experiment verifying that miR-486-5p drives tumorigenesis by directly targeting multiple negative regulators, which were involved in PTEN/PI3K/Akt, FOXO, and TGF-b/Smad2 signaling. Finally, we demonstrated that hypoxia-inducible factor-1a and TCF-12 are located at the miR-486-5p promoter, which stimulates the transcription of miR-486-5p itself. Collectively, our findings unveil miR-486-5p as a powerful prostate cancer driver that coordinates the activation of multiple oncogenic pathways and demonstrates some stimulators, which mediate the miR-486-5p signaling pathway and may be targeted for therapy.

[1]  C. Croce Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[2]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[3]  C. Croce,et al.  Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer , 2013, Proceedings of the National Academy of Sciences.

[4]  Zhaoyong Hu,et al.  Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486 , 2012, Kidney international.

[5]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[6]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[7]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[8]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Sun Young Lee,et al.  miR-486-5p induces replicative senescence of human adipose tissue-derived mesenchymal stem cells and its expression is controlled by high glucose. , 2012, Stem cells and development.

[10]  S. Arora,et al.  Exploiting Nanotechnology for the Development of MicroRNA-Based Cancer Therapeutics. , 2016, Journal of biomedical nanotechnology.

[11]  Guihua Sun,et al.  MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. , 2015, Blood.

[12]  A. Russo,et al.  miR‐20b modulates VEGF expression by targeting HIF‐1α and STAT3 in MCF‐7 breast cancer cells , 2010, Journal of cellular physiology.

[13]  Ke Huang,et al.  Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis. , 2014, International journal of oncology.

[14]  F. Booth,et al.  FoxO3a preferentially induces p27Kip1 expression while impairing muscle precursor cell‐cycle progression , 2008, Muscle & nerve.

[15]  D. Danielpour,et al.  Critical role of Smad2 in tumor suppression and transforming growth factor-beta-induced apoptosis of prostate epithelial cells. , 2009, Cancer research.

[16]  Kam M. Hui,et al.  MiR-214 Targets β-Catenin Pathway to Suppress Invasion, Stem-Like Traits and Recurrence of Human Hepatocellular Carcinoma , 2012, PloS one.

[17]  T. Tammela,et al.  MicroRNA expression profiling in prostate cancer. , 2007, Cancer research.

[18]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[19]  Qiang Sun,et al.  Direct repression of the oncogene CDK4 by the tumor suppressor miR-486-5p in non-small cell lung cancer , 2016, Oncotarget.

[20]  Vivian T. Yin,et al.  Distinct pathways in the pathogenesis of sebaceous carcinomas implicated by differentially expressed microRNAs. , 2015, JAMA ophthalmology.

[21]  K. Yanagisawa,et al.  Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. , 2008, Cancer research.

[22]  P Barbry,et al.  miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity , 2011, Cell Death and Differentiation.

[23]  Wan-qiu Zhao,et al.  miR-483-5p and miR-486-5p are down-regulated in cumulus cells of metaphase II oocytes from women with polycystic ovary syndrome. , 2015, Reproductive biomedicine online.

[24]  E. Olson,et al.  Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486 , 2010, Proceedings of the National Academy of Sciences.

[25]  C. Croce,et al.  Clinical Applications for microRNAs in Cancer , 2013, Clinical pharmacology and therapeutics.

[26]  Jie-Ping Zhu,et al.  MiR-199a inhibits the angiogenic potential of endometrial stromal cells under hypoxia by targeting HIF-1α/VEGF pathway. , 2015, International journal of clinical and experimental pathology.

[27]  Sung-Liang Yu,et al.  MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. , 2010, Cancer research.

[28]  M. Nykter,et al.  MiR‐1247‐5p is overexpressed in castration resistant prostate cancer and targets MYCBP2 , 2015, The Prostate.

[29]  K. Iwasaki,et al.  MiR-142-5p and miR-486-5p as biomarkers for early detection of chronic antibody-mediated rejection in kidney transplantation , 2017, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[30]  Chun-Chung Lee,et al.  TCF12 Protein Functions as Transcriptional Repressor of E-cadherin, and Its Overexpression Is Correlated with Metastasis of Colorectal Cancer* , 2011, The Journal of Biological Chemistry.

[31]  P. Lijnzaad,et al.  FOXO target gene CTDSP2 regulates cell cycle progression through Ras and p21Cip1/Waf1 , 2015, The Biochemical journal.

[32]  Joe W. Gray,et al.  Translating insights from the cancer genome into clinical practice , 2008, Nature.

[33]  Feng Jiang,et al.  Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers , 2010, International journal of cancer.

[34]  Ronald A. DePinho,et al.  Deletion of Hepatic FoxO1/3/4 Genes in Mice Significantly Impacts on Glucose Metabolism through Downregulation of Gluconeogenesis and Upregulation of Glycolysis , 2013, PloS one.

[35]  G. Semenza,et al.  Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. , 2014, Annual review of pathology.

[36]  N. Palanisamy,et al.  Genomic Loss of miR-486 Regulates Tumor Progression and the OLFM4 Antiapoptotic Factor in Gastric Cancer , 2011, Clinical Cancer Research.

[37]  Ricky T. Tong,et al.  Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. , 2009, Molecular cell.

[38]  Huan Yang,et al.  MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.

[39]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[40]  G. Baldwin,et al.  HIF1α expression under normoxia in prostate cancer--which pathways to target? , 2015, The Journal of urology.